SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Northwest Biotherapeutics, Inc. (NWBO) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 25/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NWBO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio180.67
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.07
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-1.48 |
$1.74M |
$-114.74M |
-6598.1% |
| 2016 |
$-0.77 |
$623K |
$-80.21M |
-12875.4% |
| 2017 |
$-0.31 |
$336K |
$-73.14M |
-21768.8% |
| 2018 |
$-0.12 |
$412K |
$-35.79M |
-8687.9% |
| 2019 |
$-0.04 |
$2.41M |
$-20.81M |
-863.6% |
| 2020 |
$-0.73 |
$1.29M |
$-529.82M |
-41039.6% |
| 2021 |
$-0.06 |
$1.01M |
$179.13M |
17823.5% |
| 2022 |
$-0.10 |
$1.68M |
$-105.03M |
-6240.8% |
| 2023 |
$-0.06 |
$1.93M |
$-62.6M |
-3240.1% |
| 2024 |
$-0.07 |
$1.38M |
$-83.78M |
-6062.1% |
